Bruker (NASDAQ:BRKR) Updates FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.100-2.150 for the period, compared to the consensus estimate of 2.120. The company issued revenue guidance of $3.6 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Bruker Stock Up 0.4%

Shares of BRKR stock traded up $0.17 on Friday, reaching $43.90. 766,439 shares of the stock were exchanged, compared to its average volume of 2,285,317. The company has a current ratio of 1.55, a quick ratio of 0.87 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average price is $37.26 and its 200 day moving average price is $42.06. The company has a market capitalization of $6.68 billion, a price-to-earnings ratio of -182.40, a PEG ratio of 2.53 and a beta of 1.12. Bruker has a twelve month low of $28.53 and a twelve month high of $56.22.

Bruker (NASDAQ:BRKR) last issued its earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The firm had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts expect that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were paid a dividend of $0.05 per share. The ex-dividend date was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s payout ratio is presently -83.33%.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of analyst reports. UBS Group boosted their target price on shares of Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a research note on Thursday. Stifel Nicolaus set a $45.00 target price on shares of Bruker in a research note on Friday. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, April 24th. The Goldman Sachs Group lowered their target price on shares of Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research note on Friday, February 13th. Finally, Guggenheim lowered their target price on shares of Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus target price of $50.54.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the transaction, the vice president owned 128,443 shares in the company, valued at $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 27.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bruker

Several large investors have recently bought and sold shares of BRKR. Los Angeles Capital Management LLC acquired a new position in Bruker in the fourth quarter valued at $26,000. Allworth Financial LP boosted its stake in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares in the last quarter. Parallel Advisors LLC boosted its stake in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares in the last quarter. Summit Securities Group LLC acquired a new position in Bruker in the fourth quarter valued at $50,000. Finally, Parkside Financial Bank & Trust raised its holdings in shares of Bruker by 144.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock valued at $70,000 after buying an additional 876 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.